NHRI holds talks on drug that reduces weight loss pills side effects
02/22/2021 03:49 PM
Lo Leu-wei (羅履維) / Photo courtesy of the NHRI
Taipei, Feb. 22 (CNA) The National Health Research Institutes (NHRI) is currently in talks with Taiwanese companies to potentially mass produce a unique nanomaterial that has been found to reduce the side effects of anti-obesity drugs, an NHRI researcher said Monday.
Lo Leu-wei (羅履維), a member of a research team at the NHRI s Institute of Biomedical Engineering and Nanomedicine, said obesity is a disease of modern civilization, with obese people comprising 40 percent of the global population, citing World Health Organization (WHO) statistics.
Revive Therapeutics signs asset purchase agreement with Newscope Capital to acquire the full rights to PharmaTher s IP relating to psilocybin
PharmaTher, a wholly-owned subsidiary of Newscope, is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals In addition to the up to C$10M purchase price, Revive will also pay Newscope a low single-digit royalty on all future net sales of products derived from the acquired assets
Revive Therapeutics Ltd. (CSE:RVV) (OTCMKTS:RVVTF) said that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement with Newscope Capital Corporation to acquire the full rights to PharmaTher Inc.’s intellectual property relating to psilocybin.
PharmaTher Announces Sale of Psilocybin Program
Newscope Capital Corporation who through its wholly-owned subsidiary, PharmaTher Inc. is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement with Revive Therapeutics Ltd. to sell the full rights to PharmaTher’s intellectual property …
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher” or the “Company”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement (the “Agreement”) with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF) to sell the full rights to PharmaTher
Ketamine study finds high death rate taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
Taipei, Jan. 25 (CNA) A study of individuals arrested for using the illegal drug ketamine for recreational purposes indicates a high rate of recidivism and a significantly higher rate of suicide, according to the government-funded National Health Research Institutes (NHRI) Monday.